

Curriculum Vitae

Narjes Saheb

H-Index: 31

Tel: +97504406505, Email: nsharifaskari@sharjah.ac.ae

Orcid ID: <http://orcid.org/0000-0003-0482-6777>

Scopus ID: 56160973000

November 10, 2025

Employment

Assistant professor, College of Medicine, University of Sharjah, Period (2023-Present)

Teaching

Basic Immunology: First-Third year MBBS (Spring 2023-Present)

Advanced Molecular Immunology: PhD course (Spring 2023-Present)

Advanced Molecular Immunopharmacology: PhD course (Spring 2023-Present)

Cell-Mediated Cytotoxicity: PhD course (Fall 2023-Present)

Cytokines and Chemokines: PhD course (Fall 2023-Present)

Monoclonal antibodies: Master course (Spring 2025- Present)

Animal Models in Molecular Biology and Therapeutics: Master course (Fall 2023-Present)

Problem-Based Learning (PBL): First year MBBS (Spring 2023-Present)

Biology (Elaine N. Marieb book): Course no. 13279 (Fall 2022-2023)

Education

Postdoctoral research associate, University of Sharjah. 2018-2022

PhD Universiti Sains Malaysia, Clinical Pharmacy 2011-2014

M.Pharm. Universiti Sains Malaysia, Clinical Pharmacy 2010-2011
Research Title:

B.Pharm. (Honours) Ajman University 2006-2010

Research Grants and Awards:

Head of Rare Genetic Disorders and Immune-dysregulation Research group

- **Regulatory Mechanisms of S100A8 and S100A9 Alarmins in Severe Asthma**
Granting Agency: Internal Grant, University of Sharjah, Sharjah, UAE (October 2024).
Amount: (120,000 AED).
Role: Principal Investigator

- **Deciphering the cause of repeated pregnancy loss by Autoantibody profiling**
Granting Agency: Internal Grant, University of Sharjah, Sharjah, UAE (2023).
Amount: (40,000 AED).
Role: Principal Investigator

- **UAE Native Plants Derived Dietary Supplement and Respiratory Inflammation**
Granting Agency: External Grant, Fujairah Research Centre, UAE (2023).
Amount: (245,000 AED).
Role: Co-Principal Investigator.

- **Transcriptomic signatures of aging in the UAE population**
Granting Agency: UOS-Skoltech AlfoL grant award (2023)
Amount: (65,000 AED).
Role: Co-Investigator

- **Dysregulation of immune inhibitory receptors in obese patients during SARS-CoV-2 infection**
Granting Agency: NIH collaboration grant between UOS and MBRU (2021-2022)
Amount: (60,000 AED).
Role: Co-Investigator

- **Identifying steroid resistance genes underlying hypo-responsiveness to steroid treatment in bronchial biopsies of severe asthmatic patients**
Granting Agency: Sheikh Hamdan award for medical sciences (2021-2023)
Amount: (180,000 AED).
Role: Co-Investigator

- **SANGGAR SANJUNG publication awards 2014, Universiti Sains Malaysia**

Research interests

My main areas of research interest are Immunopharmacology and Genetic Epidemiology.

Membership

American Society of Gene & Cell Therapy (2019-Present)

American Society for Clinical Pharmacology and Therapeutics (2019-Present)

Referee for Journals

publons.com/a/1259381/

- International Immunopharmacology
- Immunobiology
- Frontiers in Immunology
- Heliyon
- Scientific report

Publications

Researchgate

H-Index =32

i10-Index = 71

Year 2025

1. **Saheb Sharif-Askari N**, Mdkhana B, Hafezi S, Elamin OF, Eladham MW, Al-Sheakly BKS, Halwani H, Saheb Sharif-Askari F, Halwani R. **Calprotectin inhibition attenuates silica-induced lung fibrosis**. *Inflammopharmacology* 33: 2869-2881, 2025.
2. Al Qureshah, F.,**Saheb Sharif-Askari, N.**, Lau, Y. L., Tam, A. R., Singh, N., Bhattad, S., Berkun, Y., Chantratita, W., Aguilar-López, R., Shahrooei, M., Abel, L., Bastard, P., Jouanguy, E., Béziat, V., Zhang, P., Rice, C. M., Cobat, A., Zhang, S. Y., Hertzog, P. J., Casanova, J. L. and Zhang, Q. (2025) **A common form of dominant human IFNAR1 deficiency impairs IFN- α and - ω but not IFN- β -dependent immunity**. *J Exp Med.* 222.
3. Mdkhana, B., **Saheb Sharif-Askari, N.**, Cagliani, R., Al-Sheakly, B. K. S., Ramakrishnan, R. K., Saheb Sharif-Askari, F., Hachim, I. Y., Hamid, Q., Rawas-Qalaji, M. and Halwani, R. (2024) **Inhibiting DNA Sensing Pathway Controls Steroid Hyporesponsive Lung Inflammation**. *Adv Biol (Weinh).* e2400230.

4. Saheb Sharif-Askari, F.; Hafezi, S.; Hachim, I.; Mdkhana, B.; Khalid, B.; Al-Sheakly, S.; **Saheb Sharif-Askari, N.**; Selvakumar, B.; Halwani, R. **Anti-IL-4R α aptamer reduces IL-4 signaling and formation of nasal polyps.** ERJ Open Res 11: 2025.
5. Eladham MW, **Sharif-Askari NS**, Sekar P, Mdkhana B, Selvakumar B, Al-Sheakly BKS, Sharif-Askari FS, Hachim I, and Halwani R. **The role of gut leakage and immune cell miss-homing on gut dysbiosis-induced lung inflammation in a DSS mice model.** PLoS One 20: e0324230, 2025.
6. Khalid Salah Al-Sheakly, B., Saheb Sharif-Askari, F., **Saheb Sharif-Askari, N.**, Hundt, J.E. and Halwani, R. (2025) **The potential role of nanobodies in asthma therapy.** Frontiers in Pharmacology 15.
7. Khalid Salah Al-Sheakly B, Saheb Sharif-Askari F, **Saheb Sharif-Askari N**, Zakri AM, Mdkhana B, Wed Abdelaziz Eladham M, Hundt JE, Hachim I, Halwani R. **Intranasal dupilumab improves responsiveness to steroid in an asthma mouse model.** Inflamm Res. 2025;74(1):43.
8. Fahad Alsohime, **Narjes Saheb Sharif-Askari**, Nasser Saleh Alharbi, Mohammed Faraj Ayad Alosaimi, Rabih Halwani; **Insights into Silica-Induced Lung Fibrosis: Fibrotic Gene Signatures, Pathways, and Therapeutic Opportunities.** Int Arch Allergy Immunol 2025; <https://doi.org/10.1159/000548097>.
9. Alsohime F, **Saheb Sharif-Askari N**, Alharbi NS, Alosaimi MFA, Halwani R (2025) **A combination of silica and cigarette smoke extract exacerbates lung fibrosis: Unveiling a harmful synergy.** PLOS ONE 20(8): e0330762. <https://doi.org/10.1371/journal.pone.0330762>
10. Khalil B, **Saheb Sharif-Askari N**, Selvakumar B, Mdkhana B, Hachim I, Zakri A, Hundt J, Hamid Q, Halwani R. **Vitamin D3 suppresses NLRP3 inflammasome pathway and enhances steroid sensitivity in a neutrophilic steroid hyporesponsive asthma mouse model.** Inflamm Res. 2025;74(1):51.
11. Mussa BM, **Saheb Sharif-Askari N**, Sulaiman N, Abusnana S. Investigation of **Thyroid Disorders in Women with Diabetes in the United Arab Emirates: A Retrospective Cross-Sectional Study.** Womens Health Rep (New Rochelle). 2025;6(1):161-8.
12. Alsayed HAH, **Saheb Sharif-Askari N**, Saheb Sharif-Askari F, Halwani R. **Elizabethkingia Meningoseptica in Dubai, United Arab Emirates: A 7-Year Multicenter Study.** Am J Infect Control 53: 326-329, 2025.
13. GBD Collaborators (**Saheb Sharif-Askari, N**). Global, regional, and national burden of headache disorders, 1990-2021, with forecasts to 2050: A Global Burden of Disease study 2021. Cell Rep Med. 2025:102348.

14. GBD Collaborators (Saheb Sharif-Askari, N). **Global, regional, and national burden of pulmonary arterial hypertension: a systematic analysis for the Global Burden of Disease Study 2021**. *Lancet Respir Med.* 2025;13(1):69-79.
15. GBD Collaborators (Saheb Sharif-Askari, N). **Global, regional, and national burden of asthma and atopic dermatitis, 1990-2021, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021**. *Lancet Respir Med.* 2025;13(5):425-46.
16. GBD Collaborators (Saheb Sharif-Askari, N). **Global, regional, and national burden of household air pollution, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021**. *Lancet.* 2025;405(10485):1167-81.
17. GBD Collaborators (Saheb Sharif-Askari, N). **Global, regional, and national burden of epilepsy, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021**. *Lancet Public Health.* 2025;10(3):e203-e27.
18. GBD Collaborators (Saheb Sharif-Askari, N). **Global, regional, and national burden of suicide, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021**. *Lancet Public Health.* 2025;10(3):e189-e202.
19. GBD Collaborators (Saheb Sharif-Askari, N). Lee S, Son Y, Hwang J, Kim MS, Il Shin J, Yon DK, Kassebaum NJ. **Global, regional and national burden of dietary iron deficiency from 1990 to 2021: a Global Burden of Disease study**. *Nat Med.* 2025.
20. GBD Collaborators (Saheb Sharif-Askari, N). The burden of bacterial antimicrobial resistance in the WHO Eastern Mediterranean Region 1990-2021: a cross-country systematic analysis with forecasts to 2050. *Lancet Public Health.* 2025.

Year-2024

21. Saheb Sharif-Askari N, Mdkhana B, Hafezi S, Khalil BA, Al-Sheakly BK, Halwani H, et al. **Calprotectin is regulated by IL-17A and induces steroid hyporesponsiveness in asthma**. *Inflamm Res.* 2024.10.1007/s00011-024-01937-x.
22. Saheb Sharif-Askari F, Alsayed HAH, Saheb Sharif-Askari N, Halwani R. **Nirmatrelvir plus ritonavir reduces COVID-19 hospitalization and prevents long COVID in adult outpatients**. *Sci Rep.* 2024 Online ahead of print
23. Saheb Sharif-Askari N, Saheb Sharif-Askari F, Bayram OS, Hafezi S, Alsayed HAH, Kasim F, Mdkhana B, Selvakumar B, Alsafar HS, Halwani R. **Salivary autoantibodies to type I IFNs: Mirror plasma levels, predispose to severe**

- COVID-19, and enhance feasibility for clinical screening.** Heart & Lung. 2024;66:31-6.
24. **Saheb Sharif-Askari N**, Hafezi S, Saheb Sharif-Askari, Alsayed HAH, Ahmed B. M. Samrein, Alsafar HS, Halwani R. **Multiple inborn errors of type I IFN immunity in a 33-Year-old male with a fatal case of COVID-19.** Heliyon. 2024;10(8):e29338.
 25. Saheb Sharif-Askari F, Zakri AM, Alenazy MF, El-Wetidy MS, Khalid Salah Al-Sheakly B, **Saheb Sharif-Askari N**, et al. **IL-35 promotes IL-35(+)IL-10(+) Bregs and Conventional LAG3(+) Tregs in the lung tissue of OVA-Induced Asthmatic Mice.** Inflamm Res. 2024;73(10):1699-709.10.1007/s00011-024-01925-1
 26. Khalil, BA, **Saheb Sharif-Askari, N**, et al. (2024). **Vitamin D regulates COVID-19 associated severity by suppressing the NLRP3 inflammasome pathway.** PLOS one. 2024;19(5):e0302818.
 27. Saheb Sharif-Askari F, Ali Hussain Alsayed H, **Saheb Sharif-Askari N**, Saddik B, Al Sayed Hussain A, Halwani R. **Risk factors and early preventive measures for long COVID in non-hospitalized patients: analysis of a large cohort in the United Arab Emirates.** Public Health. 2024;230:198-206.
 28. Ali Hussain Alsayed H, Saheb Sharif-Askari F, **Saheb Sharif-Askari N**, Halwani R. **Clinical pharmacist interventions in an intensive care unit reduces ICU mortality at a tertiary hospital in Dubai, United Arab Emirates.** *Explor Res Clin Soc Pharm.* 2024 Mar 9;14:100431. doi: 10.1016/j.rcsop.2024.100431. eCollection 2024 Jun.
 29. Eladham MW, Selvakumar B, **Saheb Sharif-Askari N**, Saheb Sharif-Askari F, Ibrahim SM, Halwani R. **Unraveling the gut-Lung axis: Exploring complex mechanisms in disease interplay.** *Heliyon.* 2024;10(1):e24032.
 30. B. Selvakumar, M. W. Eladham, S. Hafezi, R. Ramakrishnan, I. Y. Hachim, O. S. Bayram, **Saheb Sharif-Askari N**, F. S. Sharif-Askari, S. M. Ibrahim, R. Halwani, **Allergic Airway Inflammation Emerges from Gut Inflammation and Leakage in Mouse Model of Asthma.** *Adv. Biology* 2024, 8, 2300350.
 31. GBD Collaborators (**Saheb Sharif-Askari, N**). **Global burden of vision impairment due to age-related macular degeneration, 1990–2021, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2021.** The Lancet Global Health, Volume 13, Issue 7, e1175 - e1190.
 32. GBD Collaborators (**Saheb Sharif-Askari, N**). **GBD Collaborators (Saheb Sharif-Askari, N). Global, regional, and national trends in routine childhood vaccination coverage from 1980 to 2023 with forecasts to 2030: a systematic analysis for the Global Burden of Disease Study 2023.** The Lancet, Volume 406, Issue 10500, 235 - 260

33. GBD Collaborators (Saheb Sharif-Askari, N). **Global, regional, and national burden of upper respiratory infections and otitis media, 1990-2021: a systematic analysis from the Global Burden of Disease Study 2021.** *Lancet Infect Dis.* 2024.10.1016/s1473-3099(24)00430-4.
34. GBD Collaborators (Saheb Sharif-Askari, N) **Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050.** *Lancet.* 2024;404(10459):1199-226.10.1016/s0140-6736(24)01867-1
35. GBD Collaborators (Saheb Sharif-Askari, N). **Global estimates on the number of people blind or visually impaired by Uncorrected Refractive Error: a meta-analysis from 2000 to 2020.** *Eye (Lond).* 2024;38(11):2083-101.10.1038/s41433-024-03106-0
36. GBD Collaborators (Saheb Sharif-Askari, N). **Global, regional, and national stillbirths at 20 weeks' gestation or longer in 204 countries and territories, 1990-2021: findings from the Global Burden of Disease Study 2021**
37. GBD Collaborators (Saheb Sharif-Askari, N). **Global estimates on the number of people blind or visually impaired by age-related macular degeneration: a meta-analysis from 2000 to 2020.** *Eye (Lond).* 2024;38(11):2070-82.10.1038/s41433-024-03050-z
38. GBD Collaborators (Saheb Sharif-Askari, N). **Global pattern, trend, and cross-country inequality of early musculoskeletal disorders from 1990 to 2019, with projection from 2020 to 2050.** *Med.* 2024;5(8):943-62.e6.10.1016/j.medj.2024.04.009
39. GBD Collaborators (Saheb Sharif-Askari, N). **Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.** *Lancet.* 2024;403(10440):2162-203.10.1016/s0140-6736(24)00933-4
40. GBD Collaborators (Saheb Sharif-Askari, N). **Global, regional, and national burden of HIV/AIDS, 1990-2021, and forecasts to 2050, for 204 countries and territories: the Global Burden of Disease Study 2021.** *Lancet HIV* 2024, 11, e807-e822, doi:10.1016/s2352-3018(24)00212-1.
41. GBD 2021 Demographics Collaborators (Saheb Sharif-Askari, N). **Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950-2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021.** *Lancet.* 2024 Mar 8:S0140-6736(24)00476-8. doi: 10.1016/S0140-6736(24)00476-8. Online ahead of print.

42. GBD 2021 Nervous System Disorders Collaborators (**Saheb Sharif-Askari, N**). **Global, regional, and national burden of disorders affecting the nervous system, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.** *Lancet Neurol.* 2024 Apr;23(4):344-381. doi: 10.1016/S1474-4422(24)00038-3. Epub 2024 Mar 14.
43. GBD 2021 Tuberculosis Collaborators (**Saheb Sharif-Askari, N**). **Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021.** *Lancet Infect Dis.* 2024 Mar 19:S1473-3099(24)00007-0. doi: 10.1016/S1473-3099(24)00007-0. Online ahead of print.
44. GBD 2021 Collaborators (**Saheb Sharif-Askari, N**). **Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.** *Lancet.* 2024.
45. GBD 2021 Collaborators (**Saheb Sharif-Askari, N**). **Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990-2021: a systematic analysis from the Global Burden of Disease Study 2021.** *Lancet Infect Dis.* 2024.

Year-2023

46. **Saheb Sharif-Askari N**, Hafezi S, Saheb Sharif-Askari F, Frommenwiler N, Halwani R. **Hemizygous BTK gene variant causing X-linked Agammaglobulinemia in two siblings.** *J.Clin.Immunol*, <https://doi.org/10.1007/s10875-023-01534-3>.
47. Saheb Sharif-Askari, F., **Saheb Sharif-Askari, N.**, Hafezi, S. *et al.* **Increased blood immune regulatory cells in severe COVID-19 with autoantibodies to type I interferons.** *Sci Rep* **13**, 17344 (2023).
48. Mdkhana, B, **Saheb Sharif-Askari, N**, Ramakrishnan, RK, Al-Sheakly, BK, Hafezi, S, Saheb Sharif-Askari, F, Bajbouj, K, Hamid, Q, and Halwani, R (2023). **Nucleic acid sensor STING drives remodeling and its inhibition enhances steroid responsiveness in chronic obstructive pulmonary disease.** *Plos one* **18**: e0284061.
49. Khalil, BA, **Saheb Sharif-Askari, N**, and Halwani, R (2023). **Role of inflammasome in severe, steroid-resistant asthma.** *Current Research in Immunology* **4**: 100061.

50. Jalaeddine, N, Gaudet, M, Mogas, A, Hachim, M, Senok, A, **Saheb Sharif-Askari, N**, Mahboub, B, Halwani, R, Hamid, Q, and Al Heialy, S (2023). **Cell free ACE2 RNA: A potential biomarker of COVID-19 severity.** *Respir Med* **219**: 107409.
51. Taneera, J, Khalique, A, Salima, A, Mohammed, AK, Sawan, AS, Aneis, H, Habib, P, Abdrabh, S, Elemam, NM, **Saheb Sharif-Askari, N**, et al. (2023). **Disrupting of family with sequence similarity 105, member A (Fam105a) deteriorates pancreatic β -cell physiology and insulin secretion in INS-1 cells.** *Molecular and Cellular Endocrinology* **574**: 111987.
52. Ahmed, SB, Radwan, N, Amer, S, **Saheb Sharif-Askari, N**, Mahdami, A, Samara, KA, Halwani, R, and Jelinek, HF (2023). **Assessing the Link between Diabetic Metabolic Dysregulation and Breast Cancer Progression.** *International Journal of Molecular Sciences* **24**: 11816.
53. Saddik, B., Zeidan, R., Shukla, A., Hussein, A., AlZubaidi, H., Temsah, M., Alhajjaj, M., Al-Bluwi, N., Awad, M., Alsayed, H. A. H., **Saheb Sharif-Askari, N.**, AlHano, Z., Hamid, Q., and Halwani, R. (2023). **Determining levels of knowledge, worry, anxiety and intention to get vaccinated during the recent monkeypox outbreak: a cross-sectional study from the United Arab Emirates (UAE).** *Population Medicine*, **5**(Supplement), A264.
54. Zeidan, RK, Shukla, A, Hussein, A, AlZubaidi, H, Temsah, MH, AlHajjaj, MS, Al-Bluwi, N, Awad, M, Alsayed, HAH, **Saheb Sharif-Askari, N**, et al. (2023). **Assessment of Knowledge, Perceptions, and Attitudes During the Global Mpox Outbreak in June 2022: A Cross-Sectional Study From the United Arab Emirates.** *Int J Public Health* **68**: 1606080.
55. Al Ali, T, Ashfaq, A, Saheb Sharif-Askari, N, Abusnana, S, and Mussa, BM (2023). **Investigating the Association between Diabetic Neuropathy and Vitamin D in Emirati Patients with Type 2 Diabetes Mellitus.** *Cells* **12**: 198.
56. GBD 2021 Diabetes Collaborators (**Saheb Sharif-Askari, N**). **Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021.** *Lancet*. 2023 Jun 22:S0140-6736(23)01301-6. doi: 10.1016/S0140-6736(23)01301-6. Online ahead of print.
57. Wunrow, HY, Bender, RG,... **Saheb Sharif-Askari, N**, and Wool, EE (2023). **Global, regional, and national burden of meningitis and its aetiologies, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019.** *The Lancet Neurology* **22**: 685-711.
58. Wu, Dongze **Saheb Sharif-Askari, N**, ,, **Global, regional, and national incidence of six major immune-mediated inflammatory diseases: findings**

from the global burden of disease study 2019. (2023). *EClinicalMedicine* 64: 102193.

59. Mensah George A, **Saheb Sharif-Askari, N**, ,,, et al. Global Burden of **Cardiovascular Diseases and Risks, 1990-2022**. *Journal of the American College of Cardiology*. 2023;82(25):2350-2473.

Year-2022

60. Bastard P, Vazquez S, Liu J, Laurie MT, Wang CY, Gervais A,.... Halwani R, **Saheb Sharif-Askari N**. et al. **Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs**. *Science Immunology*. 2022:eabp8966.
61. **Saheb Sharif-Askari, N.**, Saheb Sharif-Askari, F., Hafezi, S., Kalaji, Z., Temsah, M., Almuhsen, S., Alsafar, H.S., Hamid, Q. and Halwani, R. (2022d) **Airways tissue expression of type I interferons and their stimulated genes is higher in children than adults**. *Heliyon* 8, e11724.
62. **Saheb Sharif-Askari, N.**, Soares, N.C., Mohamed, H.A., Saheb Sharif-Askari, F., Alsayed, H.A.H., Al-Hroub, H., Salameh, L., Osman, R.S., Mahboub, B., Hamid, Q., Semreen, M.H. and Halwani, R. (2022e) **Saliva metabolomic profile of COVID-19 patients associates with disease severity**. *Metabolomics* 18, 81.
63. **Saheb Sharif-Askari, N.**, Alabed, M., Selvakumar, B., Mdkhana, B., Salam Bayram, O., Kalaji, Z., Hafezi, S., Elemam, N.M., Saheb Sharif-Askari, F. and Halwani, R. (2022c) **Simvastatin reduced infiltration of memory subsets of T lymphocytes in the lung tissue during Th2 allergic inflammation**. *Int Immunopharmacol* 113, 109347.
64. Sharif-Askari FS, Hafezi S, **Saheb Sharif-Askari N**, Alsayed HAH, Mdkhana B, Selvakumar B, Temsah M-H, Saddik B, Al Anouti F, and Halwani R. **Vitamin D modulates systemic inflammation in patients with severe COVID-19**. *Life Sciences* 307: 120909, 2022.
65. Hafezi, S., Saheb Sharif-Askari, F., **Saheb Sharif-Askari, N.**, Ali Hussain Alsayed, H., Alsafar, H., Al Anouti, F., Hamid, Q. and Halwani, R. (2022) **Vitamin D enhances type I IFN signaling in COVID-19 patients**. *Sci Rep* 12, 17778.

66. Saheb Sharif-Askari F, Ali Hussain Alsayed H, Tleyjeh I, **Saheb Sharif-Askari N**, Al Sayed Hussain A, Saddik B, Hamid Q, and Halwani R. **Sotrovimab Lowers the Risk of COVID-19 Related Hospitalization or Death in a Large Population Cohort in the United Arab Emirates.** *Clinical Pharmacology & Therapeutics* n/a: 2022.
67. Ali Alghamdi M, Benabdelkamel H, Masood A, **Saheb Sharif-Askari N.** et al. **Genomic, Proteomic, and Phenotypic Spectrum of Novel O-Sialoglycoprotein Endopeptidase Variant in Four Affected Individuals With Galloway-Mowat Syndrome.** *Front Genet* 13: 806190, 2022.
68. Mahmoud, S., Ganesan, S., **Saheb Sharif-Askari N.**, Cantarutti, F., Wilson, H., Ogrodzki, P., Halwani, R., Alkaabi, N. and Zaher, W.A. (2022) **Durability of antibodies post vaccination with two doses of inactivated BBIBP-CorV vaccine.** *Curr Med Res Opin* 38, 2069-2075.
69. Salameh L, Bhamidimarri PM, **Saheb Sharif-Askari N**, Dairi Y, Hammoudeh SM, Mahdami A, et al. **In Silico Bioinformatics Followed by Molecular Validation Using Archival FFPE Tissue Biopsies Identifies a Panel of Transcripts Associated with Severe Asthma and Lung Cancer.** *Cancers (Basel)*. 2022;14(7).
70. Jalaeddine N, Hachim M, Al-Hroub H, **Saheb Sharif-Askari N**, Senok A, Elmoselhi A, et al. **N6-Acetyl-L-Lysine and p-Cresol as Key Metabolites in the Pathogenesis of COVID-19 in Obese Patients.** *Front Immunol*. 2022;13:827603.
71. Jalaeddine, N, Bouzid, A, Hachim, M, **Saheb Sharif-Askari, N**, Mahboub, B, Senok, A, Halwani, R, Hamoudi, RA, and Al Heialy, S (2022). **ACE2 polymorphisms impact COVID-19 severity in obese patients.** *Scientific Reports* 12: 21491.
72. Al Sayed H, **Saheb Sharif-Askari N**, Rahimi M. **Clinically significant drug interactions between antiretroviral and co-prescribed drugs in HIV infected patients: retrospective cohort study.** *Medicine and Pharmacy Reports* [Internet]. 9Jun.2022 [cited 27Aug.2022];95(3):260-6. Available from: <https://medpharmareports.com/index.php/mpr/article/view/2305>
73. Mahboub B, Kharaba Z, Ramakrishnan RK, **Saheb Sharif Askari N**, Salameh LI, Alhariri HS, Vats MG, Erabia WT, Alshawamreh EM, Alfoteih Y, Mogas AK, Halwani R, and Hamid Q. **Continuous positive airway pressure therapy suppresses inflammatory cytokines and improves glucocorticoid responsiveness in patients with obstructive sleep apnea and asthma: A case-control study.** *Ann Thorac Med* 17: 166-172, 2022.
74. Elemam NM, Hasswan H, Aljaibeji H, **Saheb Sharif-Askari N**, Halwani R, Taneera J, et al. **Profiling Levels of Serum microRNAs and Soluble ACE2 in COVID-19 Patients.** *Life (Basel)*. 2022;12(4).

75. Saheb Sharif-Askari, F., **Saheb Sharif-Askari, N.**, Hafezi, S., Goel, S., Ali Hussain Alsayed, H., Ansari, A.W., Mahboub, B., Al-Muhsen, S., Temsah, M.H., Hamid, Q. and Halwani, R. (2022b) **Upregulation of interleukin-19 in saliva of patients with COVID-19.** *Sci Rep* **12**, 16019.
76. Al-Muhsen S, Al-Numair NS, **Saheb Sharif-Askari N**, Basamh R, Alyounes B, Jabaan A, et al. **Favipiravir Effectiveness and Safety in Hospitalized Moderate-Severe COVID-19 Patients: Observational Prospective Multicenter Investigation in Saudi Arabia.** *Front Med (Lausanne)*. 2022;9:826247.
77. Alenazy MF, Saheb Sharif-Askari F, El-Wetidy MS, **Saheb Sharif-Askari N**,..., Hamid Q, Halwani R. **Intranasal administration of abatacept enhances IL-35+ and IL-10+ producing Bregs in lung tissues of ovalbumin-sensitized asthmatic mice model.** *PLoS One*. 2022 Jun 10;16(6):e0252984. doi:10.1371/journal.pone.39082.
78. Saheb Sharif-Askari F, **Saheb Sharif-Askari N**, Hafezi S, Alsayed HAH, Mdkhana B, Temsah M-H, Hamid Q and Halwani R. **Interleukin-17, a salivary biomarker for COVID-19 severity.** *PLoS One*. Sept.

Year-2021

79. Bastard P, Gervais A, Le Voyer T, Rosain J, Philippot Q, Manry J, Michailidis E, Hoffmann H-H, Eto S, Garcia-Prat M, Bizien L, Parra-Martínez A, Yang R, Halwani R, **Saheb Sharif-Askari N**, ... Zhang Q, Cobat A, Abel L, Casanova J-L. **Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths.** *Science Immunology*. 2021;6(62):eabl4340.
80. **Saheb Sharif-Askari N**, Saheb Sharif-Askari F, Mdkhana B, Hussain Alsayed HA, Alsafar H, Alrais ZF, Hamid Q, Halwani R. **Upregulation of oxidative stress gene markers during SARS-COV-2 viral infection.** *Free Radical Biology and Medicine*. 2021; 172:688-98.
81. Saheb Sharif-Askari F, Goel S, **Saheb Sharif-Askari N**, Hafezi S, Al Heialy S, Hachim MY, Hachim IY, Mahboub B, Salameh L, Abdelrazig M, Elzain EI. **Asthma associated cytokines regulate the expression of SARS-CoV-2 receptor ACE2 in the lung tissue of asthmatic patients.** *Frontiers in Immunology*.5881.
82. Hussain Alsayed, HA, Saheb Sharif-Askari, F, **Saheb Sharif-Askari, N**, Hussain, AAS, Hamid, Q, and Halwani R, (2021). **Early administration of remdesivir to COVID-19 patients associates with higher recovery rate and lower need for ICU admission: A retrospective cohort study.** *PLoS One* 16: e0258643.

83. Alabed, M, Sultana Shaik, A, **Saheb Sharif-Askari, N**, Saheb Sharif-Askari, F, Hafezi, S, Mdkhana, B, Ratemi, E, Al-Muhsen, S, Hamid, Q, and Halwani R (2021). **Enhanced Infiltration of Central Memory T Cells to the Lung Tissue during Allergic Lung Inflammation.** International Archives of Allergy and Immunology 183: 127-141, 2022.
84. Alabed, M, Elemam, NM, Ramakrishnan, RK, **Saheb Sharif-Askari N**, Kashour, T, Hamid, Q, and Halwani R (2021). **Therapeutic effect of statins on airway remodeling during asthma** (2021). Expert Review of Respiratory Medicine: 1-8.
85. Saddik, B, Al-Bluwi, N, Shukla, A, Barqawi, H, Alsayed, HAH, **Saheb Sharif-Askari, N**, Temsah, MH, Bendardaf, R, Hamid, Q, and Halwani R*(2021). **Determinants of healthcare workers perceptions, acceptance, and choice of COVID-19 vaccines: a cross-sectional study from the United Arab Emirates.** Hum Vaccin Immunother: 1-9.
86. **Saheb Sharif-Askari N**, Sharif-Askari, FS, Mdkhana, B, Al Heialy, S, Alsafar, HS, Hamoudi, R, Hamid, Q, and Halwani R. (2020). **Enhanced expression of immune checkpoint receptors during SARS-CoV-2 viral infection.** Molecular Therapy - Methods & Clinical Development. 2021;20:109-21.
87. Hachim, I. Y., Hachim, M. Y., Talaat, I. M., López-Ozuna, V. M., **Saheb Sharif-Askari N**, Halwani, R., & Hamid, Q. **The molecular basis of gender variations in mortality rates associated with the novel coronavirus (COVID-19) outbreak.** Front. Mol. Biosci. | doi: 10.3389/fmolb.2021.728409.
88. **Saheb Sharif-Askari N**, Saheb Sharif-Askari F, Ahemd B. S., Hannawi S, Hamoudi R, Hamid Q, and Halwani R. **Enhanced expression of autoantigens during SARS-CoV-2 viral infection.** Front Immunol. 2021. doi: 10.3389/fimmu.2021.686462.
89. Saheb Sharif-Askari F, **Saheb Sharif-Askari N**, Goel S, Hafezi S, Assiri R, Al-Muhsen S, Hamid Q, Halwani R. **SARS-CoV-2 attenuates corticosteroid sensitivity by suppressing DUSP1 expression and activating p38 MAPK pathway.** European Journal of Pharmacology. 2021;908:174374.
90. Bajbouj K, Ramakrishnan RK, Saber-Ayad M, Omar HA, **Saheb Sharif-Askari N**, Shafarin J, Elmoselhi AB, Ihmaid A, AlHaj Ali S, Alalool A, Abdullah R, Hamid Q. **PRMT5 Selective Inhibitor Enhances Therapeutic Efficacy of Cisplatin in Lung Cancer Cells.** Int J Mol Sci. 2021;22(11).
91. Muhammad, JS, **Saheb Sharif-Askari, N**, Cui, Z-G, Hamad, M, and Halwani, R (2021). **SARS-CoV-2 infection-induced promoter hypomethylation as an epigenetic modulator of Heat Shock Protein A1L gene.** Frontiers in Genetics 12: 129.

92. Saheb Sharif-Askari F, **Saheb Sharif Askari N**, Goel S, Mahboub B, Ansari AW, Temsah M-H, et al. **Upregulation of IL-19 cytokine during severe asthma: a potential saliva biomarker for asthma severity.** ERJ Open Research. 2021:00984-2020.
93. Mdkhana, B, **Saheb Sharif-Askari, N**, Rakhee K., R, Swati,G, Qutayba, H, and Rabih H (2021). **Nucleic acid-sensing pathways during SARS-CoV-2 infection: expectations versus reality.** Journal of Inflammation Research. 14: 199-216.
94. Saheb Sharif-Askari F, Al-Khayyal N, Talaat I, Saheb Sharif-Askari N, Rawat S, Jundi M, Syrjanen K., Hamoudi R, Bendardaf R. (2018) **Immunohistochemical Assessment of TNFAIP3/A20 Expression Correlates with Early Tumorigenesis in Breast Cancer.** Anticancer Res. doi: 10.21873/anticancerres.11xxx (2021).
95. Goel S, Saheb Sharif-Askari F, **Saheb Sharif Askari N**, Madkhana B, Alwaa AM, Mahboub B, et al. (2021). **SARS-CoV-2 Switches 'on' MAPK and NFκB Signaling via the Reduction of Nuclear DUSP1 and DUSP5 Expression.** Front Pharmacol. ;12:631879.

Year-2020

96. **Saheb Sharif-Askari N**, Saheb Sharif-Askari, F, Mdkhana, B, Al Heialy, S, Ratemi, E, Alghamdi, M, Abusnana, S, Kashour, T, Hamid, Q, and Halwani, R (2020). **Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue.** Arch Toxicol. 2020 Dec;94(12):4037-4041.
97. **Saheb Sharif-Askari N**, Fatemeh Saheb Sharif-Askari, Masha'el Alabed, Ahmad Abou Tayoun, Tom Loney, Mohammed Uddin, Abiola Senok, Saba Al Heialy, Rifat Hamoudi, Tarek Kashour, Alawi Alsheikh-Ali, Qutayba Hamid, and Rabih Halwani. **Effect of Common Medications on the Expression of SARS-CoV-2 Entry Receptors in Kidney Tissue.** Clin Transl Sci. cts.12862.
98. Alghamdi, M.A., Mulla, J., **Saheb Sharif-Askari N**, Guzmán-Vegac, F.J., Arold, S.T., Abd-Alwahed, M., Alharbi, N., Kashour, T. and Halwani, R., 2020. **A Novel Biallelic STING1 Gene Variant Causing SAVI in Two Siblings.** Frontiers in Immunology, 11, p.3509.
99. Sharif-Askari, F.S., **Saheb Sharif-Askari N**, Goel, S., Fakhri, S., Al-Muhsen, S., Hamid, Q. and Halwani, R. **Are patients with chronic rhinosinusitis with nasal polyps at a decreased risk of COVID-19 infection?** Int Forum Allergy Rhinol. 2020; 10.

100. Ansari, AW, Sharif-Askari, FS, Jayakumar, MN, Mohammed, AK, **Saheb Sharif-Askari N**, Venkatachalam, T, Mahboub, B, Schmidt, RE, Hamoudi, RA, Halwani, R, et al. (2020). **Azithromycin Differentially Alters TCR-Activated Helper T Cell Subset Phenotype and Effector Function**. *Front Immunol* 11: 556579.
101. **Saheb Sharif-Askari N**, Saheb Sharif-Askari F, Alabed M, Tamsah M-H, Al Heialy S, Hamid Q, Halwani R. **Airways Expression of SARS-CoV-2 Receptor, ACE2, and TMPRSS2 Is Lower in Children Than Adults and Increases with Smoking and COPD**. *Molecular Therapy - Methods & Clinical Development* 2020; 18:1-6.
102. **Saheb Sharif-Askari N**, Sharif-Askari FS, Al Heialy S, Hamoudi R, Kashour T, Hamid Q, Halwani R. **Cardiovascular medications, and regulation of Covid-19 receptors expression**. *International Journal of Cardiology Hypertension* 2020:100034.
103. Bendardaf R, Saheb Sharif-Askari F, **Saheb Sharif-Askari N**, Yousuf Guraya S, A AlMadhi S, Abusnana S. **Incidence and Clinicopathological Features of Breast Cancer in the Northern Emirates: Experience from Sharjah Breast Care Center**. *Int J Womens Health*. 2020; 12:893-899. Published 2020 Oct 27.
104. Saheb Sharif-Askari F, **Saheb Sharif-Askari N**, Halwani R, Abusnana S, Hamoudi R, Sulaiman N. **Low Vitamin D Serum Level Is Associated with HDL-C Dyslipidemia and Increased Serum Thrombomodulin Levels of Insulin-Resistant Individuals**. *Diabetes Metab Syndr Obes*. 13:1599-1607 (2020).
105. **Saheb Sharif-Askari N**, Saheb Sharif-Askari F, Guraya SY, Bendardaf R, Hamoudi R. **Integrative systematic review meta-analysis and bioinformatics identifies MicroRNA-21 and its target genes as biomarkers for colorectal adenocarcinoma**. *International Journal of Surgery*. 73:113-22 (2020).
106. Saheb Sharif-Askari, F., **N. Saheb Sharif-Askari**, A. Guella, A. Alabdullah, H. Bashar Al Sheleh, A. Maher Hoory AlRawi, E. Sami Haddad, Q. Hamid, R. Halwani and R. Hamoudi (2020). **"Blood Neutrophil-to-Lymphocyte Ratio and Urine IL-8 Levels Predict the Type of Bacterial Urinary Tract Infection in Type 2 Diabetes Mellitus Patients"**. *Infection and drug resistance* 13: 1961-1970.

Year-2019

107. **Saheb Sharif-Askari N**, Sharif HA, Saheb Sharif-Askari F, Hamid Q, Abusnana S, Hamoudi R. **Association between body mass index and asthma severity in Arab pediatric population: A retrospective study**. *PLoS ONE* 14 (12), e0226957 (2019).

108. **Saheb Sharif-Askari N**, Hamoudi R, Saheb Sharif-Askari F, Abusnana S, Aljaibeji H, Taneera J, et al. **Prediabetes and diabetes prevalence and risk factors comparison between ethnic groups in the United Arab Emirates.** Scientific Reports. 9(1):17437 (2019).
109. Saheb Sharif-Askari F, Sobti A, **Saheb Sharif-Askari N**, Hachim MY, Williams L, Zhou Y, Hopper C, Hamoudi R. **Logistic regression prediction model identify type 2 diabetes mellitus as a prognostic factor for human papillomavirus-16 associated head and neck squamous cell carcinoma.** PLOS ONE 14, e0217000, (2019).
110. Bendardaf R, Saheb Sharif-Askari F, **Saheb Sharif-Askari N**, Syrjanen K. & Pyrhonen S. **Cytoplasmic E-Cadherin Expression Is Associated with Higher Tumour Level of VEGFA, Lower Response Rate to Irinotecan-based Treatment and Poorer Prognosis in Patients With Metastatic Colorectal Cancer.** Anticancer Research 39, 1953-1957 (2019).

Year-2018

111. **Saheb Sharif-Askari N**, Bendardaf R, Saheb Sharif-Askari F, El Tabbal A, El Ayan. **Patterns of bladder cancer in the Benghazi, Libya over the past three decades.** Scientific Reports 8, 10822, (2018).
112. Bendardaf R, Saheb Sharif-Askari F, **Saheb Sharif-Askari N**, Syrjanen K. & Pyrhonen S. (2018) **Patients with hMLH1 or/and hMSH2-deficient Metastatic Colorectal Cancer Are Associated with Reduced Levels of Vascular Endothelial Growth Factor-1 Expression and Higher Response Rate to Irinotecan-based Regimen.** Anticancer Res November 38 (11) 6399-6404 (2018).

Year-2017

113. Saheb Sharif-Askari, F., **Saheb Sharif-Askari N**, Syed Sulaiman SA. **Anticoagulation Therapy in Patients with Chronic Kidney Disease.** Adv Exp Med Biol 906: 101-114 (2017).
114. Saheb Sharif-Askari F, **Saheb Sharif-Askari N**, Javadi M, Gholami K. **Adverse Drug Reactions Reported to the Drug and Poison Information Center.** PLoS ONE12(9): e0185450 (2017).

Year-2015

115. **Saheb Sharif-Askari N**, Syed Sulaiman SA, Saheb Sharif-Askari F, Al Sayed Hussain A. **Adverse drug reaction-related hospitalisations among patients**

with heart failure at two hospitals in the United Arab Emirates. Int J Clin Pharm 37(1): 105-112 (2015).

Year-2014

116. **Saheb Sharif-Askari N**, Syed Sulaiman SA, Saheb Sharif-Askari F, Al Sayed Hussain A, Tabatabai S, Abdullatif Al-Mulla A. **Hospitalized heart failure patients with preserved vs. reduced ejection fraction in Dubai, United Arab Emirates: a prospective study.** Eur J Heart Fail. 16(4): 454-460 (2014).
117. **Saheb Sharif-Askari N**, Syed Sulaiman SA, Saheb Sharif-Askari F, Al Sayed Hussain A, Abdullatif Al-Mulla A. **Assessment of guideline adherence in hospitalised heart failure patients with systolic dysfunction in Dubai, United Arab Emirates.** Int J Cardiol 172 (3):e491-e493 (2014).
118. Saheb Sharif-Askari F, Syed Sulaiman SA, **Saheb Sharif-Askari N**, Al Sayed Hussain A **Development of an Adverse Drug Reaction Risk Assessment Score among Hospitalized Patients with Chronic Kidney Disease.** PLoS ONE 9(4): e95991(2014).
119. Saheb Sharif-Askari F, Syed Sulaiman SA, **Saheb Sharif-Askari N**, Al Sayed Hussain A, Railey MJ. **Adverse Outcomes of Anticoagulant Use among Hospitalized Patients with Chronic Kidney Disease: A Comparison of the Rates of Major Bleeding Events between Unfractionated Heparin and Enoxaparin.** PLoS ONE 9(9): e106517 (2014).

Book Chapter

Saheb Sharif-Askari F, Syed Sulaiman SA, **Saheb Sharif-Askari N. Anticoagulation Therapy in Patients with Chronic Kidney Disease. In: Thrombosis and Embolism: from Research to Clinical Practice: Springer, In press.**

Conference Papers

Saheb Sharif-Askari N, et al. Insights into Silica-Induced Lung Fibrosis: Fibrotic Gene Signatures, Pathways, and Therapeutic Opportunities. Q-Hamid International Conference, February 15th, 2025. Abstract and oral Presentation.

Saheb Sharif-Askari N, et al. Calprotectin is regulated by IL-17A and induces steroid hyporesponsiveness in asthma. DUPHAT: Dubai International Pharmaceuticals & Technologies, January 10th 2024. Abstract and oral Presentation.

Balachandar S, Mariam Wed E, Shirin H, et al. **Saheb Sharif-Askari N.** Development of OVA induced allergic airway inflammation emerge with gut inflammatory manifestations. *European Respiratory Journal*. 2023;62(suppl 67):PA4410.

Saheb Sharif-Askari N, Syed Sulaiman SA, Saheb Sharif-Askari F. Adverse drug reaction-related hospitalisations in heart failure patients. DUPHAT: Dubai International Pharmaceuticals & Technologies, March 10-12th 2014. Abstract and oral Presentation.

Saheb Sharif-Askari F, Syed Sulaiman SA, **Saheb Sharif-Askari N.** Development of An Adverse Drug Reaction Risk Assessment Score Among Hospitalized Patients with Chronic Kidney Disease. DUPHAT: Dubai International Pharmaceuticals & Technologies, March 10-12th 2014. Abstract and oral Presentation.

Saheb Sharif-Askari N, Syed Sulaiman SA, Saheb Sharif-Askari F. Factors Associated with ACE Inhibitors/Angiotensin II Receptor Antagonists Underutilization among Hospitalised Heart Failure Patients in a Middle Eastern Country. ACCP13: The Asian Conference on Clinical Pharmacy, September 13-15th 2013. Abstract.

Saheb Sharif-Askari F, Syed Sulaiman SA, **Saheb Sharif-Askari N**. Adverse Outcomes of Anticoagulant Use in Hospitalized Patients with Chronic Kidney Disease: A Propensity Analysis Study. ACCP13: The Asian Conference on Clinical Pharmacy, September 13-15th 2013. Oral Presentation.